Please login to the form below

Not currently logged in

Orphan drug status for Mapreg

Biotech company Mapreg announced on March 18 that it has been granted orphan drug status by the EU commission.

Biotech company Mapreg announced on March 18 that it has been granted orphan drug status by the EU commission. Its lead compound MAP4343, a medication for treating spinal cord injury, has now been entered in the European Community register of orphan drugs.

A drug becomes known as 'orphan' if it is designed to treat a rare disease, illnesses that affect only five out 10,000 people in the EU. Etienne-Emile Baulieu, president of Mapreg, said: "The granting of orphan drug status in the European Union is an important step for Mapreg and for the future benefit of patients having suffered a spinal chord injury."

Orphan drug status qualifies Mapreg for scientific assistance for developing MAP4343 from the European Medicines Agency (EMEA) and exemption from regulatory approval fees. Over 20,000 spinal chord injury cases are reported every year in the West and operative therapeutic remedies and care for patients can cost between Ä1m and 2m.

Baulieu said: "The results on animal models are without parallel and we want to move forward to initiate the first clinical trails." Phase I clinical trails of MAP4343 could now begin at the end of 2008.

20th March 2008


Featured jobs

Subscribe to our email news alerts


Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

The truth is out there: Patients first
Patient centricity, patient focus, patients first – words that are on everyone’s lips these days. But what do they really mean? Where does the patient voice fit in? And what...
mHealth: The revolution will not be digital
Could mHealth, which has been growing exponentially in recent years, be the answer we have been looking for to address our population health challenge? Could mHealth save healthcare?...
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine....